VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 126 filers reported holding VIRIDIAN THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $275,046 | -86.8% | 17,930 | -79.5% | 0.00% | -87.5% |
| Q2 2023 | $2,079,722 | -32.7% | 87,420 | -28.1% | 0.01% | -82.6% |
| Q1 2023 | $3,092,410 | +115.9% | 121,557 | +147.9% | 0.05% | +70.4% |
| Q4 2022 | $1,432,517 | -63.4% | 49,042 | -74.3% | 0.03% | -64.0% |
| Q3 2022 | $3,918,000 | +89.7% | 191,029 | +7.0% | 0.08% | +31.6% |
| Q2 2022 | $2,065,000 | -31.2% | 178,451 | +10.0% | 0.06% | -28.8% |
| Q1 2022 | $3,001,000 | +37.8% | 162,281 | +47.3% | 0.08% | +17.6% |
| Q4 2021 | $2,178,000 | +488.6% | 110,175 | +389.6% | 0.07% | +580.0% |
| Q3 2021 | $370,000 | – | 22,501 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,699,865 | $68,684,566 | 13.41% |
| COMMODORE CAPITAL LP | 2,189,659 | $55,704,925 | 8.48% |
| Fairmount Funds Management LLC | 1,369,623 | $34,843,209 | 5.99% |
| Paradigm Biocapital Advisors LP | 2,085,698 | $53,060,157 | 5.03% |
| Octagon Capital Advisors LP | 1,185,000 | $30,146,400 | 4.34% |
| Logos Global Management LP | 950,000 | $24,168,000 | 3.46% |
| TCG Crossover Management, LLC | 663,610 | $16,882,238 | 3.29% |
| ACUTA CAPITAL PARTNERS, LLC | 168,000 | $4,273,920 | 3.15% |
| Vivo Capital, LLC | 1,678,207 | $42,693,586 | 2.96% |
| TANG CAPITAL MANAGEMENT LLC | 692,925 | $17,628,012 | 2.63% |